Early versus Delayed Fixed Dose Combination Abacavir/Lamivudine/Zidovudine in Patients with HIV and Tuberculosis in Tanzania
- 1 December 2009
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 25 (12), 1277-1285
- https://doi.org/10.1089/aid.2009.0100
Abstract
Fixed dose combination abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) among HIV-1 and tuberculosis (TB)-coinfected patients was evaluated and outcomes between early vs. delayed initiation were compared. In a randomized, pilot study conducted in the Kilimanjaro Region of Tanzania, HIV-infected inpatients with smear-positive TB and total lymphocyte count 3 were randomized to initiate ABC/3TC/ZDV either 2 (early) or 8 (delayed) weeks after commencing antituberculosis therapy and were followed for 104 weeks. Of 94 patients screened, 70 enrolled (41% female, median CD4 count 103 cells/mm3), and 33 in each group completed 104 weeks. Two deaths and 12 serious adverse events (SAEs) were observed in the early arm vs. one death, one clinical failure, and seven SAEs in the delayed arm (p = 0.6012 for time to first grade 3/4 event, SAE, or death). CD4 cell increases were +331 and +328 cells/mm3, respectively. TB-immune reconstitution inflammatory syndromes (TB-IRIS) were not observed in any subject. Using intent-to-treat (ITT), missing = failure analyses, 74% (26/35) vs. 89% (31/35) randomized to early vs. delayed therapy had HIV RNA levels p = 0.2182) and 66% (23/35) vs. 74% (26/35), respectively, had HIV RNA levels p = 0.6026). In an analysis in which switches from ABC/3TC/ZDV = failure, those receiving early therapy were less likely to be suppressed to p = 0.030]. TB-IRIS was not observed among the 70 coinfected subjects beginning antiretroviral treatment. ABC/3TC/ZDV was well tolerated and resulted in steady immunologic improvement. Rates of virologic suppression were similar between early and delayed treatment strategies with triple nucleoside regimens when substitutions were allowed.Keywords
This publication has 40 references indexed in Scilit:
- Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy TrialPLOS ONE, 2009
- Invasive Disease Caused by Nontuberculous Mycobacteria, TanzaniaEmerging Infectious Diseases, 2009
- Antiretroviral Therapy during Tuberculosis Treatment and Marked Reduction in Death Rate of HIV-Infected Patients, Thailand1Emerging Infectious Diseases, 2007
- Complications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory SyndromeThe Journal of Infectious Diseases, 2007
- Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimensAIDS, 2007
- Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacyAIDS, 2007
- Determinants of Immune Reconstitution Inflammatory Syndrome in HIV Type 1–Infected Patients with Tuberculosis after Initiation of Antiretroviral TherapyClinical Infectious Diseases, 2004
- Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infectionThorax, 2004
- Paradoxical Reactions of Tuberculosis in Patients With the Acquired Immunodeficiency Syndrome Who Are Treated With Highly Active Antiretroviral TherapyArchives of Internal Medicine, 2002
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998